Gut-on-a-chip market seen reaching $1.38 billion by 2030

The gut-on-a-chip market is projected to grow from $0.77 billion in 2025 to $1.38 billion by 2030, driven by demand for better intestinal disease models, alternatives to animal testing and advances in microbiome research. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Gut-on-a-chip platforms give researchers a more realistic way to study intestinal function, disease mechanisms and drug response than traditional lab models. - The technology is becoming more relevant as gastrointestinal disease rates rise and drug developers look for better in-vitro testing tools. - The market's expected growth signals broader adoption across pharmaceutical research, biotechnology and precision medicine.

What happened: - The gut-on-a-chip market is projected to rise from $0.77 billion in 2025 to $0.87 billion in 2026. - The market is forecast to reach $1.38 billion by 2030. - The report projects a 12.7% CAGR for the 2025-2026 period and a 12.3% CAGR through 2030. - The Business Research Company published the market outlook on Sept. 17, 2026. - The company offered a free sample of the gut-on-a-chip market report. - The company also provided the full gut-on-a-chip market report.

The details: - A gut-on-a-chip is a microfluidic device designed to replicate the structure and function of the human intestine on a small laboratory chip. - The device uses living human intestinal cells in narrow channels that mimic fluid flow and mechanical motions such as peristalsis. - Researchers use the technology to study digestion, nutrient absorption, microbiome interactions and intestinal diseases. - Market growth in the recent period has been supported by microfluidic engineering improvements, stronger human cell culture research, and early organ-on-chip adoption in academic settings. - Rising investment in biotechnology research infrastructure has also supported adoption. - Future growth drivers include personalized medicine, precision drug testing, microbiome research, integrated multi-organ chip platforms and regulatory support for alternative testing methods. - The report highlights future trends including real-time gut physiology simulation, microbiome interaction modeling, high-throughput toxicity screening and stem cell-based intestinal tissue replication. - The report says rising gastrointestinal disease incidence is a key market driver. - The report links that rise to unhealthy eating habits and higher consumption of processed foods. - In January 2024, the American Cancer Society said colorectal cancer remained the second leading cause of cancer-related deaths in the United States, with about 53,010 deaths projected for 2024, up from 52,550 the year before.

Between the lines: - Demand for gut-on-a-chip tools reflects a broader shift in drug development toward human-relevant models that can reduce reliance on animal testing. - The market outlook suggests the strongest opportunities may come from technologies that combine gut models with other organ systems or with microbiome analysis. - North America's lead in 2025 points to the region's deeper biotech base, while Asia-Pacific's expected growth suggests rising research investment there.

What's next: - The market report expects continued uptake as pharmaceutical companies expand in-vitro testing and personalized medicine programs. - More integrated multi-organ chip systems are likely to shape the next wave of product development. - The company says its 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated trend analysis. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Gut-on-a-chip is moving from a niche research tool to a broader platform for disease study and drug testing, and the market forecast points to sustained double-digit growth through 2030.